KYMR
Neutral signalScored 2026-10-02 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Kymera Therapeutics, Inc.
- Nom
- Kymera Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $9.1B
- Employés
- 273
- PDG
- Nello Mainolfi
- Site web
- https://www.kymeratx.com
- Marché
- ARVNCCCCGLUENRIX
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 30 000 titres (~3 343 200,00 $ US)
- Insiders
- Mainolfi Nello
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$281,671
Avg sell (VWAP, 90d window) $117.41 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$30,423 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-01
- Last synced
-
2026-10-07 09:54:19
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-01 | Mainolfi Nello | Sell · S · 10b5-1 | 262 | $116.12 | $30,423 | Form 4 |
| 2026-09-04 | Adams Brian | Sell · S | 2,137 | $117.57 | $251,247 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-02 Drivers: fundamentals. Moteurs : fondamentaux.
KYMR is a pre-revenue biotech with a strong liquidity buffer (score: 85) but severely deteriorating fundamentals (score: 25), characterized by widening losses and negative free cash flow.
The first sentence of the analysis written for KYMR on 2026-10-02 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 10.47 · operating margin -891% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | -794.3% | -475.0% | -186.7% | -330.2% | -137.4% | |
| Ebitda Margin | -773.1% | -459.4% | -182.2% | -323.9% | -134.1% | |
| Operating Profit Margin | -891.3% | -555.8% | -210.6% | -344.4% | -138.0% | |
| Pretax Profit Margin | -795.0% | -475.6% | -187.0% | -330.6% | -137.6% | |
| Continuous Operations Profit Margin | -795.0% | -475.6% | -187.0% | -330.6% | -137.6% | |
| Net Profit Margin | -794.4% | -475.6% | -187.0% | -330.6% | -137.6% | |
| Bottom Line Profit Margin | -794.4% | -475.6% | -187.0% | -330.6% | -137.6% | |
| Current Ratio | 10.470 | 7.530 | 4.730 | 5.879 | 4.876 | |
| Quick Ratio | 10.470 | 7.530 | 4.730 | 5.879 | 4.876 | |
| Solvency Ratio | -1.858 | -1.520 | -0.793 | -1.344 | -0.669 | |
| Cash Ratio | 4.290 | 1.775 | 1.283 | 0.959 | 0.518 | |
| Price To Earnings Ratio | -21.087 | -13.500 | -10.103 | -8.697 | -30.378 | |
| Price To Earnings Growth Ratio | -0.885 | -0.740 | 0.828 | -0.233 | -0.273 | |
| Forward Price To Earnings Growth Ratio | -0.885 | -0.740 | 0.828 | -0.233 | -0.273 | |
| Price To Earnings Diluted Ratio | -21.087 | -13.500 | -10.103 | -8.697 | -30.378 | |
| Price To Earnings Diluted Growth Ratio | -0.885 | -0.740 | 0.828 | -0.233 | -0.273 | |
| Price To Book Ratio | 4.157 | 3.613 | 3.762 | 2.746 | 6.629 | |
| Price To Sales Ratio | 167.510 | 64.136 | 18.908 | 28.748 | 41.834 | |
| Price To Free Cash Flow Ratio | -28.021 | -14.561 | -10.822 | -8.634 | -23.340 | |
| Price To Operating Cash Flow Ratio | -28.195 | -15.522 | -14.451 | -8.794 | -23.629 | |
| Debt To Assets Ratio | 0.047 | 0.090 | 0.147 | 0.029 | 0.030 | |
| Debt To Equity Ratio | 0.052 | 0.105 | 0.214 | 0.035 | 0.039 | |
| Debt To Capital Ratio | 0.049 | 0.095 | 0.177 | 0.034 | 0.038 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.103 | 1.170 | 1.458 | 1.231 | 1.318 | |
| Working Capital Turnover Ratio | 0.064 | 0.124 | 0.235 | 0.133 | 0.265 | |
| Operating Cash Flow Ratio | -2.799 | -2.870 | -1.200 | -2.146 | -1.393 | |
| Operating Cash Flow Sales Ratio | -5.941 | -4.132 | -1.308 | -3.269 | -1.770 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.006 | 1.066 | 1.335 | 1.019 | 1.012 | |
| Debt Service Coverage Ratio | -21.639 | -868.418 | -730.617 | -861.676 | -557.971 | |
| Interest Coverage Ratio | -1,403.213 | -1,050.743 | -844.541 | -916.227 | -574.457 | |
| Short Term Operating Cash Flow Coverage Ratio | -16.930 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -2.831 | -2.216 | -1.214 | -8.831 | -7.178 | |
| Capital Expenditure Coverage Ratio | -160.725 | -15.150 | -2.982 | -53.979 | -80.743 | |
| Dividend Paid And Capex Coverage Ratio | -160.725 | -15.150 | -2.982 | -53.979 | -80.743 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -20.760 | -13.811 | -10.200 | -8.540 | -30.896 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 100.0% | 0.0% | 0.0% |
| Ebit Margin | -794.3% | ▼-319.3% | ▼-409.6% |
| Ebitda Margin | -773.1% | ▼-313.7% | ▼-398.6% |
| Operating Profit Margin | -891.3% | ▼-335.5% | ▼-463.3% |
| Pretax Profit Margin | -795.0% | ▼-319.4% | ▼-409.8% |
| Continuous Operations Profit Margin | -795.0% | ▼-319.4% | ▼-409.8% |
| Net Profit Margin | -794.4% | ▼-318.8% | ▼-409.4% |
| Bottom Line Profit Margin | -794.4% | ▼-318.8% | ▼-409.4% |
| Current Ratio | 10.470 | ▲2.940 | ▲3.773 |
| Quick Ratio | 10.470 | ▲2.940 | ▲3.773 |
| Solvency Ratio | -1.858 | ▼-0.338 | ▼-0.621 |
| Cash Ratio | 4.290 | ▲2.516 | ▲2.525 |
| Price To Earnings Ratio | -21.087 | ▼-7.587 | ▼-4.334 |
| Price To Earnings Growth Ratio | -0.885 | ▼-0.145 | ▼-0.625 |
| Forward Price To Earnings Growth Ratio | -0.885 | ▼-0.145 | ▼-0.625 |
| Price To Earnings Diluted Ratio | -21.087 | ▼-7.587 | ▼-4.334 |
| Price To Earnings Diluted Growth Ratio | -0.885 | ▼-0.145 | ▼-0.625 |
| Price To Book Ratio | 4.157 | ▲0.544 | ▼-0.025 |
| Price To Sales Ratio | 167.510 | ▲103.374 | ▲103.283 |
| Price To Free Cash Flow Ratio | -28.021 | ▼-13.460 | ▼-10.945 |
| Price To Operating Cash Flow Ratio | -28.195 | ▼-12.673 | ▼-10.077 |
| Debt To Assets Ratio | 0.047 | ▼-0.043 | ▼-0.021 |
| Debt To Equity Ratio | 0.052 | ▼-0.053 | ▼-0.037 |
| Debt To Capital Ratio | 0.050 | ▼-0.046 | ▼-0.029 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.103 | ▼-0.067 | ▼-0.153 |
| Working Capital Turnover Ratio | 0.064 | ▼-0.060 | ▼-0.100 |
| Operating Cash Flow Ratio | -2.799 | ▲0.071 | ▼-0.717 |
| Operating Cash Flow Sales Ratio | -5.941 | ▼-1.809 | ▼-2.657 |
| Free Cash Flow Operating Cash Flow Ratio | 1.006 | ▼-0.060 | ▼-0.082 |
| Debt Service Coverage Ratio | -21.640 | ▲846.778 | ▲586.425 |
| Interest Coverage Ratio | -1403.213 | ▼-352.470 | ▼-445.377 |
| Short Term Operating Cash Flow Coverage Ratio | -16.930 | ▼-16.930 | ▼-13.544 |
| Operating Cash Flow Coverage Ratio | -2.831 | ▼-0.615 | ▲1.623 |
| Capital Expenditure Coverage Ratio | -160.725 | ▼-145.575 | ▼-98.009 |
| Dividend Paid And Capex Coverage Ratio | -160.725 | ▼-145.575 | ▼-98.009 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -20.760 | ▼-6.949 | ▼-3.919 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $6.57B | $3.02B | $1.49B | $1.35B | $3.05B | |
| Enterprise value | $6.29B | $2.99B | $1.46B | $1.30B | $3.02B | |
| EV / Sales | 160.50x | 63.45x | 18.59x | 27.66x | 41.42x | |
| EV / Op. cash flow | -27.02x | -15.36x | -14.21x | -8.46x | -23.40x | |
| EV / Free cash flow | -26.85x | -14.40x | -10.64x | -8.31x | -23.11x | |
| EV / EBITDA | -20.76x | -13.81x | -10.20x | -8.54x | -30.90x | |
| Net debt / EBITDA | 0.91x | 0.15x | 0.18x | 0.34x | 0.31x | |
| Current ratio | 10.47x | 7.53x | 4.73x | 5.88x | 4.88x | |
| Income quality | 0.75x | 0.87x | 0.70x | 0.99x | 1.29x | |
| Graham net-net | $8 | $5 | $4 | $5 | $6 | |
| Tax burden | 99.9% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.1% | 100.1% | 100.1% | 100.1% | 100.2% | |
| Working capital | $788.0M | $442.5M | $319.6M | $348.1M | $358.7M | |
| Invested capital | $873.5M | $540.4M | $420.7M | $370.3M | $380.0M | |
| Return on assets | -17.9% | -22.9% | -25.5% | -25.7% | -16.5% | |
| Operating ROA | -25.7% | -33.7% | -28.1% | -26.7% | -18.4% | |
| Return on tangible assets | -17.9% | -22.9% | -25.5% | -25.7% | -16.5% | |
| Return on equity | -19.7% | -26.8% | -37.2% | -31.6% | -21.8% | |
| Return on invested capital | -20.9% | -28.3% | -33.3% | -30.1% | -19.4% | |
| Return on capital employed | -21.1% | -28.7% | -33.8% | -30.3% | -19.6% | |
| Earnings yield | -4.7% | -7.4% | -9.9% | -11.5% | -3.3% | |
| Free cash flow yield | -3.6% | -6.9% | -9.2% | -11.6% | -4.3% | |
| Capex / Op. cash flow | -0.6% | -6.6% | -33.5% | -1.9% | -1.2% | |
| Capex / Depreciation | 17.4% | 174.1% | 967.2% | 95.3% | 66.6% | |
| Capex / Sales | 3.7% | 27.3% | 43.9% | 6.1% | 2.2% | |
| SG&A / Sales | 174.0% | 135.0% | 70.0% | 93.6% | 49.9% | |
| R&D / Sales | 807.7% | 510.4% | 240.6% | 350.8% | 188.1% | |
| Stock comp / Sales | 152.8% | 116.9% | 54.9% | 75.8% | 34.3% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 7d | 87d | 20d | 1d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 7d | 87d | 20d | 1d | |
| Cash conversion cycle | 0d | 7d | 87d | 20d | 1d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-30 Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Kymera Therapeutics, Inc. (NASDAQ: KYMR) breached their fiduciary duties to shareholders.
- 2026-09-15 Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-10 Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup''s Biopharma Back to School Summit 2026 Transcript Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup''s Biopharma Back to School Summit 2026 Transcript
- 2026-09-04 Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? Kymera Therapeutics (KYMR) reported earnings 30 days ago. What''s next for the stock?
- 2026-09-04 Atlas Venture Life Science Advisors LLC Decreases Stock Holdings in Kymera Therapeutics, Inc. $KYMR Atlas Venture Life Science Advisors LLC lessened its stake in Kymera Therapeutics, Inc. (NASDAQ: KYMR) by 37.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,847,541 shares of the company''s stock after selling 1,730,467 shares during the quarter.
- 2026-09-03 Can KT-621 Mark a Turning Point for Kymera Therapeutics? KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.
- 2026-09-02 Kymera Therapeutics to Participate in Upcoming September Investor Conferences WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events: Wells Fargo 21st Annual Healthcare Conference in Boston, MA on September 9 at 8:00 AM ET; Citi 2026 Biopharma Back to School Summit in New York, NY on September 10 at 11:20 AM ET; H.C.
- 2026-09-01 Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses Enrollment completed in KT-621 BROADEN2 Phase 2b AD trial with topline data expected by year-end 2026; Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with topline data expected in late 2027 WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will present two posters featuring previously reported data from the BroADen Phase 1b trial evaluating KT-621, its first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD).
- 2026-08-31 215,588 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Bank of New York Mellon Corp Bank of New York Mellon Corp purchased a new position in shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 215,588 shares of the company''s stock, valued at approximately $24,721,000. Bank of New York
- 2026-08-06 KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.